Insider and congress filings

CVS Health Corp. (CVS)

NYSE · Healthcare · 358 insider transactions · 260 congress trades · last filed 2 months agoS&P 500

8
Open-market insider filings shown
123d
Median delay on the insider filings, in business days
Form 4 is due in two business days
4 buys·4 sells
Purchases and sales in the filings shown
Get a push when an insider at CVS Health Corp. trades.

Free on iOS and Android.

About CVS Health Corp.

from the company's filings and listing, as of Oct 23, 2026
Exchange
NYSE
Sector
Healthcare
Industry
Medical - Healthcare Plans
Chief executive
J. David Joyner
Employees
259,500
Listed since
-
Market value
$120.8B
Price to earnings (12 mo)
24.7
Net income per share, as reported (12 mo)
$3.84
Dividend yield
2.82%

www.cvshealth.com

Company news

2 articles · newest first
HeadlineSourceDate
CVS Health opens three MinuteClinic locations in MassachusettsThe new clinics are in Charlestown, Beverly and Swampscott, and the Charlestown site is the first MinuteClinic in Boston.Company releaseOct 20, 2026
CVS Health unveils first pharmacy-focused CVS Pharmacy in Boston areaCVS Health said nearly 20 pharmacy-focused locations are set to open in select communities across the country in 2026.Company releaseOct 7, 2026

Written by GetSignal with AI from the company's own SEC filings and press releases; each article links to its source. Not investment advice. Company news from every company we cover

Earnings

6 reported quarters · next on Nov 4, 2026
QuarterEPSEPS expectedRevenueRevenue expectedResult
Q2 FY2026reported Aug 5, 2026$2.58$1.85$106.1B$100.0BEPS beatRevenue beat
Q1 FY2026reported May 6, 2026$2.57$2.18$100.4B$95.0BEPS beatRevenue beat
Q4 FY2025reported Feb 10, 2026$1.09$1.00$105.7B$103.7BEPS beatRevenue beat
Q3 FY2025reported Oct 29, 2025$1.60$1.37$102.9B$98.8BEPS beatRevenue beat
Q2 FY2025reported Jul 31, 2025$1.81$1.46$98.9B$94.5BEPS beatRevenue beat
Q1 FY2025reported May 1, 2025$2.25$1.70$94.6B$93.7BEPS beatRevenue in line

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

Executive pay

as filed for fiscal 2025 · proxy filed Apr 3, 2026
ExecutiveSalaryStock awardsOtherTotal
J. David JoynerPresident and Chief Executive Officer$1.5M$14.5M$5.1M$21.2M
Prem S. ShahExecutive Vice President and Group President$1.1M$7.2M$5.1M$13.4M
Steven H. NelsonExecutive Vice President and President, Aetna$1.0M$5.8M$4.8M$11.6M
Tilak MandadiExecutive Vice President, Ventures and Chief Experience and Technology Officer$1.0M$5.6M$4.4M$11.0M
Brian O. NewmanExecutive Vice President and Chief Financial Officer$697K$5.6M$3.1M$9.4M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 1 executive who has since left the company is named in that filing and not shown here. Read the filing

Institutional holders

13F positions as of Jun 30, 2026
HolderValueSharesShares vs prior qtr% of shares out
BlackRock, Inc.$12.7B123,223,409-2.1%9.66%
Vanguard Capital Management LLC$8.6B83,315,369+0.8%6.53%
Capital World Investors$7.8B74,951,955-3.0%5.87%
State Street Corp$6.2B60,283,408+1.6%4.74%
Dodge & Cox$5.2B50,012,765-3.4%3.92%
Wellington Management Group LLP$3.5B33,801,113+49.8%2.65%
Geode Capital Management, LLC$3.1B29,899,653+1.5%2.34%
FMR LLC$3.0B28,920,617-7.3%2.27%
Vanguard Portfolio Management LLC$2.8B26,637,259+2.5%2.09%
Capital Research Global Investors$2.5B24,329,151+21.6%1.91%
T. Rowe Price Associates, Inc.$2.5B24,203,884+1.8%1.90%
Bank of America Corp$2.4B23,188,670+148.0%1.82%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

Tracked fund managers holding CVS

5 managers
ManagerValueSharesShare of book
Glenview CapitalLarry Robbins$499.1M4,824,7999.1%
Viking Global InvestorsAndreas Halvorsen$379.0M3,663,3611.1%
Holocene Advisors$310.5M3,001,6840.7%
Alyeska Investment Group$174.4M1,685,4400.4%
Walleye Capital$84.2M813,9360.3%

5 of the 97 fund managers we track list CVS shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.

Know when the next CVS filing is reported.

GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.

Open-market insider trades

8 filings shown · newest filing first
InsiderActionSharesPriceValueTrade dateDelay
(business days)
Larry RobbinsDirectorSold370,462$93.45$34.6MMay 21, 2026filed May 21, 20260d
Larry RobbinsDirectorSold · 4 lines1,018,000$93.82$95.5MMay 20, 2026filed May 21, 20261d
Larry RobbinsDirectorSold · 2 lines1,983,538$94.45$187.3MMay 19, 2026filed May 21, 20262d
Tilak MandadiEVP, Chief Exp & Tech OfficerSold69,551$89.58$6.2MMay 8, 2026filed May 11, 20261d
Steven H. NelsonEVP and President, AetnaBought24$53.70$1KJan 23, 2025filed Jan 27, 2026252d
Heidi B. CapozziEVP and Chief People OfficerBought35$56.47$2KSep 9, 2024filed Oct 14, 2025274d
Heidi B. CapozziEVP and Chief People OfficerBought10$62.24$622Oct 2, 2024filed Oct 14, 2025257d
Heidi B. CapozziEVP and Chief People OfficerBought35$56.85$2KOct 23, 2024filed Oct 14, 2025243d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (20)
InsiderEventSharesDate
James David ClarkSVP, Cont & Chief Acct OfficerTax withholding454Jun 26, 2026
Amy Compton-PhillipsEVP, Chief Medical OfficerTax withholding7,618May 31, 2026
Brian NewmanEVP, Chief Financial OfficerTax withholding2,478May 31, 2026
Fernando AguirreDirectorDisposed to issuer1,563May 21, 2026
Fernando AguirreDirectorDisposed to issuer30,437May 20, 2026
Larry RobbinsDirectorSwaps sold378,000May 21, 2026
Larry RobbinsDirectorStock award3,860May 14, 2026
Douglas H. ShulmanDirectorStock award2,895May 14, 2026
Anne A. FinucaneDirectorStock award3,088May 14, 2026
Alecia A. DecoudreauxDirectorStock award2,895May 14, 2026
Michael F. MahoneyDirectorStock award3,474May 14, 2026
John E. GallinaDirectorStock award2,895May 14, 2026
C. David Brown IIDirectorStock award1,544May 14, 2026
Guy P. SansoneDirectorStock award1,447May 14, 2026
Leslie V. NorwalkDirectorStock award1,447May 14, 2026
J. Scott KirbyDirectorStock award1,447May 14, 2026
Jeffrey R. BalserDirectorStock award2,058May 14, 2026
Fernando AguirreDirectorStock award1,563May 14, 2026
Heidi B. CapozziEVP and Chief People OfficerTax withholding1,334Apr 1, 2026
Heidi B. CapozziEVP and Chief People OfficerStock award74,695Mar 31, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are. Purchases and sales of options, warrants, preferred stock or another share class are listed here too, by what was traded. They are not trades in this stock, so no price is given for them.

Congress trades in CVS

20 disclosures of 260 on record · median 22d of the 45 allowed

Since the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 25, 2026), not the member's result. Not investment advice.

MemberTypeActionAmount disclosedStock since the tradeTrade dateDisclosedDelay
Ro KhannaStockSale$1,001 - $15,000-0.7%After the saleS&P 500 -0.5% · -0.2 pts vs S&P 500Aug 24, 2026Sep 4, 202611d
Alan ArmstrongSelfStockPurchase$1,001 - $15,000+33.4%S&P 500 +19.8% · +13.5 pts vs S&P 500Mar 27, 2026Jul 21, 2026116d
Ro KhannaStockPurchase$1,001 - $15,000+4.4%S&P 500 +0.1% · +4.4 pts vs S&P 500Jun 2, 2026Jul 6, 202634d
Ro KhannaStockPurchase$1,001 - $15,000+13.9%S&P 500 +5.4% · +8.4 pts vs S&P 500May 1, 2026Jun 9, 202639d
Ro KhannaStockPurchase$1,001 - $15,000-2.5%S&P 500 +2.8% · -5.3 pts vs S&P 500May 15, 2026Jun 9, 202625d
Ro KhannaStockPurchase$1,001 - $15,000+19.7%S&P 500 +10.8% · +8.9 pts vs S&P 500Apr 13, 2026May 11, 202628d
Michael T. McCaulStockPurchase$15,001 - $50,000+21.9%S&P 500 +10.2% · +11.7 pts vs S&P 500Feb 20, 2026Mar 10, 202618d
Ro KhannaStockSale$1,001 - $15,000+26.0%After the saleS&P 500 +10.5% · +15.5 pts vs S&P 500Feb 24, 2026Mar 9, 202613d
John BoozmanJointStockPurchase$1,001 - $15,000+25.6%S&P 500 +9.5% · +16.1 pts vs S&P 500Jan 29, 2026Feb 15, 202617d
Michael T. McCaulStockSale$15,001 - $50,000+15.9%After the saleS&P 500 +9.5% · +6.4 pts vs S&P 500Jan 13, 2026Feb 11, 202629d
Ro KhannaStockSale$1,001 - $15,000+25.6%After the saleS&P 500 +9.5% · +16.1 pts vs S&P 500Jan 29, 2026Feb 6, 20268d
Dwight EvansStockSale$1,001 - $15,000+19.8%After the saleS&P 500 +15.3% · +4.5 pts vs S&P 500Nov 21, 2025Dec 19, 202528d
Lisa C. McClainSpouseStockSale$1,001 - $15,000+21.9%After the saleS&P 500 +11.7% · +10.2 pts vs S&P 500Oct 30, 2025Nov 21, 202522d
Lisa C. McClainSpouseStockPurchase$1,001 - $15,000+21.9%S&P 500 +11.7% · +10.2 pts vs S&P 500Oct 30, 2025Nov 21, 202522d
Lisa C. McClainSpouseStockSale$1,001 - $15,000+19.6%After the saleS&P 500 +11.4% · +8.2 pts vs S&P 500Oct 31, 2025Nov 21, 202521d
Michael T. McCaulStockSale$15,001 - $50,000+13.4%After the saleS&P 500 +10.9% · +2.5 pts vs S&P 500Oct 27, 2025Nov 10, 202514d
Val T. HoyleSpouseStockSale$1,001 - $15,000+22.2%After the saleS&P 500 +14.2% · +8.0 pts vs S&P 500Sep 23, 2025Oct 10, 202517d
Val T. HoyleSpouseStockPurchase$1,001 - $15,000+66.2%S&P 500 +30.6% · +35.5 pts vs S&P 500Oct 29, 2024Sep 12, 2025318d
Michael T. McCaulStockSale$50,001 - $100,000+31.1%After the saleS&P 500 +17.8% · +13.3 pts vs S&P 500Aug 22, 2025Sep 11, 202520d
Ro KhannaStockPurchase$1,001 - $15,000+52.1%S&P 500 +20.4% · +31.7 pts vs S&P 500Aug 4, 2025Sep 9, 202536d

Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in CVS, filterable by party, chamber, type and account.

Members of Congress reporting a position

10 members · estimate, as of Oct 22, 2026

10 members report a position (estimated). The largest estimated position is in the $50,001 - $100,000 band.

MemberParty, chamberEstimated positionShare of their portfolio
Harriet M. HagemanRepublican · House$50,001 - $100,0003.0%
Sheldon WhitehouseDemocrat · Senate$50,001 - $100,0000.3%
Gilbert Ray Cisneros, Jr.Democrat · House$15,001 - $50,0000.1%
Derek TranDemocrat · House$15,001 - $50,0007.8%
Lucy McBathDemocrat · House$15,001 - $50,0000.4%
Gary C. PetersDemocrat · Senate$15,001 - $50,0000.5%
Shelley Moore CapitoRepublican · Senate$15,001 - $50,0000.7%
John BoozmanRepublican · Senate$1,001 - $15,0000.4%
Dwight EvansDemocrat · House$1,001 - $15,0005.9%
Robert BresnahanRepublican · House$1,001 - $15,0000.1%

Estimate, as of Oct 22, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.

Questions

Are insiders buying or selling CVS?

Across the 8 most recent open-market filings shown here, 4 were purchases and 4 were sales.

Which members of Congress have traded CVS?

Ro Khanna, Alan Armstrong, Michael T. McCaul, John Boozman, Dwight Evans, Lisa C. McClain and others disclosed CVS transactions in the filings shown here.

Which members of Congress hold CVS?

10 members of Congress report a position in CVS in the estimate we hold as of Oct 22, 2026. The two largest estimated positions belong to Harriet M. Hageman and Sheldon Whitehouse; Gilbert Ray Cisneros, Jr. holds one of the next largest, in the $15,001 - $50,000 band. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.

Is CVS in the S&P 500 or the Nasdaq 100?

CVS Health Corp. is a current member of the S&P 500, per the membership list we hold as of Oct 26, 2026. Current members of either index get a page here whatever their filing history.

How quickly are CVS trades disclosed?

Insider filings on this page reached the public a median of 123 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 22 days, against the 45 the STOCK Act allows.

How to read a Form 4

A DECISION THE INSIDER MADE

POpen-market purchase. Bought with their own money at the market price.
SOpen-market sale. Sold on the market. A sale marked scheduled was set up in advance under a Rule 10b5-1 plan, often months before.

COMPENSATION PLUMBING

AStock award. Granted as pay, not bought.
MOption exercise. Converting options already held into shares.
FTax withholding. Shares handed back to the company to pay the tax on a grant.
GGift. Given away, with no money changing hands.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

Data as of Oct 26, 2026.

Related companies

traded by the same members

See every company we track